Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis

Journal of Surgical Oncology

Volumn 97, Issue 3, 2008, Pages 284-290

  Arrington, Sarah A ^a   Damron, Timothy A ^a   Mann, Kenneth A ^a   Allen, Matthew J ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Animal model; Biomechanics; Bisphosphonate; Bone metastasis; Radiation therapy

Indexed keywords

ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE METASTASIS; BONE STRENGTH; BONE STRUCTURE; BREAST CANCER; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOLYSIS; PRIORITY JOURNAL; TRABECULAR BONE; TUMOR XENOGRAFT;

EID: 39749198620     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20949     Document Type: Article

References (19)

1. 1 Clemons M, Dranitsaris G, Cole D, et al.: Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 2006 ; 11: 227–233.
2. 2 Liauw W, Segelov E, Lih A, et al.: Off‐trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer 2005 ; 5: 89.
3. 3 Body JJ: Bisphosphonates for malignancy‐related bone disease: Current status, future developments. Support Care Cancer 2006 ; 14: 408–418.
4. 4 Diel IJ, Solomayer EF, Bastert G: Treatment of metastatic bone disease in breast cancer: Bisphosphonates. Clin Breast Cancer 2000 ; 1: 43–51.
5. 5 Kohno N, Aogi K, Minami H, et al.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo‐controlled trial. J Clin Oncol 2005 ; 23: 3314–3321.
6. 6 Arrington SA, Schoonmaker JE, Damron TA, et al.: Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone 2006 ; 38: 359–367.
7. 7 Peng H, Sohara Y, Moats RA, et al.: The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007 ; 67: 9346–9355.
8. 8 Yoneda T, Williams PJ, Hiraga T, et al.: A bone‐seeking clone exhibits different biological properties from the MDA‐MB‐231 parental human breast cancer cells and a brain‐seeking clone in vivo and in vitro. J Bone Miner Res 2001 ; 16: 1486–1495.
9. 9 Erben R: Embedding of bone samples in methylmethacrylate: An improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 1997 ; 45: 307–313.
10. 10 Goblirsch M, Mathews W, Lynch C, et al.: Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 2004 ; 161: 228–234.
11. 11 Keene JS, Sellinger DS, McBeath AA, et al.: Metastatic breast cancer in the femur. A search for the lesion at risk of fracture. Clin Orthop Relat Res 1986: 282–288.
12. 12 Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982 ; 50: 893–899.
13. 13 Gainor BJ, Buchert P: Fracture healing in metastatic bone disease. Clin Orthop Relat Res 1983: 297–302.
14. 14 Frassica DA: General principles of external beam radiation therapy for skeletal metastases. Clin Orthop Relat Res 2003: S158–S164.
15. 15 Mirels H: Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989: 256–264.
16. 16 Krempien R, Huber PE, Harms W, et al.: Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer 2003 ; 98: 1318–1324.
17. 17 Kurth AH, Kim SZ, Sedlmeyer I, et al.: Treatment with ibandronate preserves bone in experimental tumour‐induced bone loss. J Bone Joint Surg Br 2000 ; 82: 126–130.
18. 18 Kurth AA, Kim SZ, Sedlmeyer I, et al.: Ibandronate treatment decreases the effects of tumor‐associated lesions on bone density and strength in the rat. Bone 2002 ; 30: 300–306.
19. 19 Body JJ, Bartl R, Burckhardt P, et al.: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998 ; 16: 3890–3899.